

## LYXOR ALTERNATIVE UCITS

# UPSURGE IN COMPLEX MERGERS AND ACQUISITIONS BODES WELL FOR MERGER ARBITRAGE



**Drew Figdor**  
Portfolio Manager  
TIG Advisors, LLC


The new US tax code has triggered an upsurge in complex mergers and acquisitions («M&A») creating a strong outlook for research-intensive merger arbitrage strategies, explains TIG Advisors, LLC's («TIG») Drew Figdor.

When President Donald Trump introduced the biggest overhaul to the US tax code in a generation at the end of 2017, he unleashed a flurry of M&A, including the multi-billion-dollar tie-ups announced by Walt Disney Company and 21<sup>st</sup> Century Fox, and CVS Health Corporation and Aetna. Not only were these the biggest deals of the year, they were also among the most complex.

At \$68.4bn and \$67.8bn respectively, the Walt Disney and CVS Health transactions helped to lift the value of US deals in 2017's fourth quarter to \$352.8bn, making it the most active quarter in a year when transactions totalled \$1.3trn<sup>1</sup>. Early 2018 saw similarly frenetic, yet complex, deal making. Indeed, February's correction in equity markets even encouraged deal flow as target companies became 10-20% cheaper.

President Trump's package of tax reforms made a big difference. The centrepiece was a big cut in corporations' income tax rate, from 35% to 21%, which cleared up uncertainty about how to price deals, as well as freeing up corporate cash to help finance them. Against a backdrop of low interest rates, open credit markets and a clear

direction in government policy, the tax reform gave CEOs the confidence and cash that they needed to make plan opportunistic deals.



<sup>1</sup> Source: Mergermarket.com; Global & Regional M&A Report, Q4, 2017

Source: Mergermarket.com

## COMPLEX DEALS CAN OFFER BETTER PRICING

This upsurge in deal activity and regulatory reform in tax and health care bode well for merger arbitrage strategies that do intensive research on complex deals, rather than those that focus on simpler transactions. Many of the current wave of M&A transactions have convoluted structures and are cross-border or hostile. Arbitrating them can be a research-intensive process, requiring skill and experience – consequently they offer greater rewards to those investors equipped to analyse them.

“One of the things that is significant is that when you have big regulatory change the companies need to adapt quickly”, explains Drew Figdor, Portfolio Manager at TIG Advisors, LLC the New York-based global merger arbitrage specialist. “So, we are seeing opportunistic bidding, hostile bids, companies in discussion, offer prices as a starting point. Deals are being done on an aggressive basis, which fits into our strategy because we are looking for where the market prices risk and opportunity inefficiently”.

“In many of these deals there is a significant amount of uncertainty as to whether they will be completed. This is true of a hostile deal, versus a friendly announced deal. In this low interest rate environment, the market prices certainty very efficiently – it prices uncertainty very inefficiently”.

A growing amount of capital has been allocated to mutual funds and even ETFs that focus on simpler, agreed mergers where they arbitrage the spread between the acquiring company and target company’s stock prices from the deal’s announcement to completion. Such is the weight of money directed at agreed deals that the reward, in terms of the deal spread, has shrunk. By contrast, the more complex and uncertain deals, many of which are hostile, cannot be commoditised in this magnitude and offer far higher rewards.

“One of the key points is that uncertainty is where you get much better pricing”, asserts Mr. Figdor. “So, a friendly announced deal trades at a 0-2% gross spread; you earn that over a 3-6-month period. An uncertain deal is anything from a 7-20% gross spread and you can earn that over a shorter or longer period. We focus on where our research and other tools give us the opportunity to create value that is not correlated to the market”.

January 2018’s contest to acquire Ablynx, a Belgian biopharmaceutical company, illustrates the potential rewards. In early January, Novo Nordisk, a global pharmaceutical company, bid for Ablynx at €30.5 a share. Ablynx’s management rejected the offer as under valuing the company. After meeting potential bidders at a JP Morgan healthcare conference, TIG’s analysts recognized the value of Ablynx’s asset platform and its

## SPEED READ

- The US tax reform gave CEOs the confidence and cash that they needed to make plan opportunistic deals.
- Many of the current wave of M&A transactions have convoluted structures, are cross-border or hostile.
- The more complex and uncertain deals cannot be commoditised and offer higher rewards than simple, agreed mergers.
- Volatility and mild correction in equity prices, as in February 2018, can lead to better spread prices, and encourages CEOs to bid more aggressively and opportunistically.

late-stage drug, Caplacizumab. TIG bought a position in the low €30s, anticipating that a higher bidder would emerge. After conducting their research, TIG’s analysts became more confident that the company would be sold and grew its position. On January 30, Sanofi, another global pharmaceutical company, announced an agreed deal at €45.

## GROWING CROSS-BORDER M&A VALUES

But it’s not just the US where M&A activity is buoyant. Growing economic activity has lifted deal activity in Europe, and 2017’s \$1.32trn of cross-border deals accounted for 41.9% of the year’s M&A by value, the second highest level since the financial crisis<sup>2</sup>. From a technical perspective, the stocks of the acquiring and target companies trade on different exchanges in different time zones, making it difficult to match the respective positions. More fundamentally, the shareholder in the company being acquired may not want to hold stock in an overseas company denominated in a foreign currency. Furthermore, only a few merger arbitrage specialists are prepared to put in the work, possibly including overseas travel, needed to evaluate these deals.

“These deals are mis-priced on a technical basis because they don’t trade at the same time”, says Mr. Figdor. “The target price in US drops a couple of percent daily because there is no way to set the hedge up. There is also a shareholder perspective. If European mutual funds, for example, don’t have the desire or ability to hold US stocks, they are willing sellers. Lastly, there is the research on the deal. So, if you need to go have breakfast in London or Germany to meet the CEO, fewer competitors have the desire to make that effort. That reduces number of competitors and increases the spread opportunity”.

<sup>2</sup>Source: Mergermarket.com; Global & Regional M&A Report, Q4, 2017.



**J. B. Barthon**  
Strategist



**M. Jamai**  
Fund Analyst

Lyxor Asset Management

Merger arbitrage could benefit from a unique opportunity set in 2018, driven by a shifting fiscal regime and strong sector dynamics. Times are favorable: US asset values are high, digitalization is soaring, funding costs remain low, and executive confidence is bright.

After the tax reform was voted in, companies with high tax rates and strong operational profits were re-rated. However, implications for corporate activity are only starting to unfold. Companies are yet to decide how they will put their tax savings and repatriated foreign cash to work. Alongside organic growth and distributions to shareholders M&A will have its share.

Consolidation will be another key theme. The TMT, healthcare and industrial sectors, which face structural shifts, are set to consolidate further. Creators of content, for instance, will seek to gain scale and leverage as new distribution platforms proliferate. Broadcasters might also be active as TV station ownership regulations loosen. Companies facing technological disruption or lackluster revenue growth are also acquisition candidates. As usual, the first movers tend to force competitors to follow.

Political pressures, antitrust risk, sensitive cross-border deals, elevated valuations, and more hostile acquisitions suggest 2018 will not be short of complex deals that are the true playground for merger specialists.

## REGULATION AND RISK

Risk and bad outcomes can be good; and there are always perceived risks from anti-trust regulation. This risk, especially the perception of risk, can create opportunity. For example, an arbitrageur can advantageously reverse the spread of a complex antitrust transaction that is ultimately blocked by regulatory bodies such as the US Department of Justice (“DoJ”). Mr. Figdor cites the 2015 example of the merger between Applied Materials, the US semiconductor company, and its Japanese rival, Tokyo Electron. The DoJ scuppered the deal after voicing competition concerns. Mr. Figdor’s TIG had been long the deal for six months, but after continuous research anticipated the difficulties and switched to a short leaving it well positioned when the deal broke.

As for the higher rates that appear likely in the US and elsewhere, gently rising rates tend to lead to greater M&A deal spreads and, therefore, higher merger arbitrage returns. If rising rates cause a mild correction in equity prices, as in February 2018, that can also benefit M&A arbitrage returns as it creates volatility, which can lead to better spread prices, and encourages CEOs to bid more aggressively and opportunistically. However, if rates spike higher and trigger a correction of 20% or more then that is negative for merger arbitrage. “Corrections of more than 20% are negative for our strategy”, says Mr. Figdor. “They start to affect the confidence of CEOs. So, corrections are very helpful. Bear markets are not so helpful”.

## A STRONG OUTLOOK

Short of a bear market, Mr. Figdor believes that M&A activity will accelerate in 2018 from its already high levels. With complex deals “trading way too wide”, he anticipates research-intensive strategies are well positioned to succeed in this current environment.

Yet, as the weight of money has compressed deal spreads to a point where they do not justify the risks, Mr. Figdor believes it will be harder to find competitive returns in agreed deals. He concludes: “Parts of this business have been commoditised and parts are unable to be commoditised”.

## DISCLAIMER

The circumstances in which this publication has been produced are such that it is not appropriate to characterize it as independent investment research as referred to in MiFID and that it should be treated as a marketing communication even if it contains a research recommendation. This publication is also not subject to any prohibition on dealing ahead of the dissemination of investment research. However, Lyxor is required to have policies to manage the conflicts which may arise in the production of its research, including preventing dealing ahead of investment research.

This material has been prepared solely for informational purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell any security or financial instrument, or to participate in any investment strategy. This material does not purport to summarize or contain all of the provisions that would be set forth in any offering memorandum. Any purchase or sale of any securities may be made only pursuant to a final offering memorandum. No advisory relationship is created by the receipt of this material. This material should not be construed as legal, business or tax advice. A more robust discussion of the risks and tax considerations involving in investing in a fund is available from the more complete disclosures incorporated into the offering documentation for such fund.

This material has not been prepared in regard to specific investment objectives, financial situations, or the particular needs of any specific entity or person. Investors should make their own appraisal of the risks and should seek their own financial advice regarding the appropriateness of investing in any securities or financial instrument or participating in any investment strategy. Before you decide to invest in any account or fund, you should carefully read the relevant client agreements and offering documentation. No representation is made that your investment objectives will be achieved. This material is not intended for use by retail customers.

Any descriptions involving investment process, risk management, portfolio characteristics or statistical analysis are provided for illustrative purposes only, will not apply in all situations, and may be changed without notice. Past performance is not indicative of future results, and it is impossible to predict whether the value of any fund or index will rise or fall over time.

While the information in this material has been obtained from sources deemed reliable, neither Société Générale ("SG"), Lyxor Asset Management S.A.S. ("Lyxor AM") nor their affiliates guarantee its accuracy, timeliness or completeness. We are under no obligation to update or otherwise revise such information if and when it changes. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice. SG, Lyxor AM and their affiliates assume no fiduciary responsibility or liability for any consequences, financial or otherwise, arising from an investment in any security or financial instrument described herein or in any other security, or from the implementation of any investment strategy. Lyxor AM and its affiliates may from time to time deal in, profit from the trading of, hold, have positions in, or act as market-makers, advisers, brokers or otherwise in relation to the securities and financial instruments described herein. Service marks appearing herein are the exclusive property of SG and its affiliates, as the case may be.

Hedge funds may invest in futures and other derivative instruments. Futures trading and other derivatives may permit extremely high degrees of leverage and expose the funds to, among other things, volatility, market illiquidity, market risks, legal risks and operational risks. Hedge funds may be exposed to risks relating to non-domestic markets, including, without limitation, risks relating to currency exchange, tax,

lack of liquidity, market manipulation, political instability and transaction costs. An investment in a hedge fund is subject to a total loss.

This presentation contains the views of Lyxor AM analysts and/or strategies. The views espoused in this presentation may differ from opinions and recommendations produced by other departments of SG.

Note about Indices: Indices are not available for direct investment. A comparison to an index is not meant to imply that an investment in a fund is comparable to an investment in the funds or securities represented by such index. A fund is actively managed while an index is a passive index of securities. Indices are not investable themselves, and thus do not include the deduction of fees and other expenses associated with an investment in a fund. Not all the funds that comprise indices cited herein are suitable for U.S. Investors as a result of, among other things, the implementation of the Volcker Rule. Please see the offering documentation for these funds for more details.

**Notice to U.S. Investors:** Any potential investment in any securities or financial instruments, the categories of which are described herein, may not be suitable for all investors. Any prospective investment will require you to represent that you are an "accredited investor", as defined in Regulation D under the Securities Act of 1933, as amended, and a "qualified purchaser", as defined in Section 2(a)(51) of the Investment Company Act of 1940, as amended (the "40 Act"). The securities and financial instruments described herein may not be available in all jurisdictions.

Investments in or linked to hedge funds are highly speculative and may be adversely affected by the unregulated nature of hedge funds and the use of trading strategies and techniques that are typically prohibited for funds registered under the '40 Act. Also, hedge funds are typically less transparent in terms of information and pricing and have much higher fees than registered funds. Investors in hedge funds may not be afforded the same protections as investors in funds registered under the '40 Act including limitations on fees, controls over investment policies and reporting requirements.

**Notice to Canadian Investors:** Any potential investment in any securities or financial instruments, the categories of which are described herein, may not be suitable for all investors. Any prospective investment will require you to represent that you are a "permitted client", as defined in Canadian Regulation National Instrument 31-103, and an "accredited investor", as defined in National Instrument 45-106. The securities and financial instruments described herein may not be available in all jurisdictions of Canada.

For more information, U.S. and Canadian investors and recipients should contact Lyxor Asset Management Inc., 1251 Avenue of the Americas, New York, NY 10020 or [invest@lyxor.com](mailto:invest@lyxor.com).

**Notice to U.K. Investors:** This communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorised and regulated by the Financial Conduct Authority in the UK under Registration Number 435658.

Source: This document has been prepared by Lyxor Asset Management S.A.S., 17 cours Valmy, 92800 Puteaux. Lyxor AM is a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/UE) and AIFM (2011/61/EU) Directives. Lyxor AM is also registered with the U.S. Commodity Futures Trading Commission as a registered commodity pool operator and a commodity trading advisor.

© COPYRIGHT 2018 LYXOR ASSET MANAGEMENT ALL RIGHTS RESERVED

**LYXOR**  
Asset Management  
SOCIÉTÉ GÉNÉRALE GROUP

Lyxor Asset Management - Tours Société Générale  
17 Cours Valmy - 92987 Paris La Défense Cedex - France  
[www.lyxor.com](http://www.lyxor.com) - [solutions@lyxor.com](mailto:solutions@lyxor.com)